These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1765 related articles for article (PubMed ID: 24780763)

  • 21. In Vitro Activity of Ceftolozane Alone and in Combination with Tazobactam against Extended-Spectrum-β-Lactamase-Harboring Enterobacteriaceae.
    Melchers MJ; van Mil AC; Mouton JW
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4521-5. PubMed ID: 25987635
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.
    Castanheira M; Duncan LR; Mendes RE; Sader HS; Shortridge D
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263073
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ceftolozane-Tazobactam Activity against Pseudomonas aeruginosa Clinical Isolates from U.S. Hospitals: Report from the PACTS Antimicrobial Surveillance Program, 2012 to 2015.
    Shortridge D; Castanheira M; Pfaller MA; Flamm RK
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28483953
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.
    Zhanel GG; Chung P; Adam H; Zelenitsky S; Denisuik A; Schweizer F; Lagacé-Wiens PR; Rubinstein E; Gin AS; Walkty A; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2014 Jan; 74(1):31-51. PubMed ID: 24352909
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activity of ceftolozane/tazobactam against Gram-negative isolates among different infections in Hong Kong: SMART 2017-2019.
    Karlowsky JA; Lob SH; Khan A; Chen WT; Woo PCY; Seto WH; Ip M; Leung S; Wong QW; Chau RWY; DeRyke CA; Young K; Motyl MR; Sahm DF
    J Med Microbiol; 2022 Apr; 71(4):. PubMed ID: 35451945
    [No Abstract]   [Full Text] [Related]  

  • 26. Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam and Comparators Tested Against
    Sader HS; Carvalhaes CG; Streit JM; Doyle TB; Castanheira M
    Microb Drug Resist; 2021 Mar; 27(3):342-349. PubMed ID: 32762605
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012).
    Flamm RK; Farrell DJ; Sader HS; Jones RN
    J Antimicrob Chemother; 2014 Jun; 69(6):1589-98. PubMed ID: 24562613
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacterales isolates recovered from intensive care unit patients in Spain: The SUPERIOR multicentre study.
    García-Fernández S; García-Castillo M; Bou G; Calvo J; Cercenado E; Delgado M; Pitart C; Mulet X; Tormo N; Mendoza DL; Díaz-Regañón J; Cantón R;
    Int J Antimicrob Agents; 2019 May; 53(5):682-688. PubMed ID: 30769199
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009-2011).
    Sader HS; Farrell DJ; Flamm RK; Jones RN
    Diagn Microbiol Infect Dis; 2014 Apr; 78(4):443-8. PubMed ID: 24492025
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ceftolozane/tazobactam for the treatment of complicated urinary tract and intra-abdominal infections.
    Bassetti M; Righi E
    Future Microbiol; 2015; 10(2):151-60. PubMed ID: 25689527
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials.
    Popejoy MW; Paterson DL; Cloutier D; Huntington JA; Miller B; Bliss CA; Steenbergen JN; Hershberger E; Umeh O; Kaye KS
    J Antimicrob Chemother; 2017 Jan; 72(1):268-272. PubMed ID: 27707990
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Susceptibility trends of ceftolozane/tazobactam and comparators when tested against European Gram-negative bacterial surveillance isolates collected during 2012-18.
    Sader HS; Carvalhaes CG; Duncan LR; Flamm RK; Shortridge D
    J Antimicrob Chemother; 2020 Oct; 75(10):2907-2913. PubMed ID: 32653914
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the
    Yin D; Wu S; Yang Y; Shi Q; Dong D; Zhu D; Hu F;
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30617091
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.
    Cho JC; Fiorenza MA; Estrada SJ
    Pharmacotherapy; 2015 Jul; 35(7):701-15. PubMed ID: 26133315
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro activity of flomoxef and comparators against Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis producing extended-spectrum β-lactamases in China.
    Yang Q; Zhang H; Cheng J; Xu Z; Xu Y; Cao B; Kong H; Ni Y; Yu Y; Sun Z; Hu B; Huang W; Wang Y; Wu A; Feng X; Liao K; Shen D; Hu Z; Chu Y; Lu J; Su J; Gui B; Duan Q; Zhang S; Shao H
    Int J Antimicrob Agents; 2015 May; 45(5):485-90. PubMed ID: 25600890
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro activity of ceftolozane/tazobactam against phenotypically defined extended-spectrum β-lactamase (ESBL)-positive isolates of Escherichia coli and Klebsiella pneumoniae isolated from hospitalized patients (SMART 2016).
    Karlowsky JA; Kazmierczak KM; Young K; Motyl MR; Sahm DF
    Diagn Microbiol Infect Dis; 2020 Apr; 96(4):114925. PubMed ID: 31954597
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antimicrobial activity of ceftolozane-tazobactam tested against gram-negative contemporary (2015-2017) isolates from hospitalized patients with pneumonia in US medical centers.
    Carvalhaes CG; Castanheira M; Sader HS; Flamm RK; Shortridge D
    Diagn Microbiol Infect Dis; 2019 May; 94(1):93-102. PubMed ID: 30642717
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Goodlet KJ; Nicolau DP; Nailor MD
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923865
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activity of ceftolozane-tazobactam and comparators when tested against Gram-negative isolates collected from paediatric patients in the USA and Europe between 2012 and 2016 as part of a global surveillance programme.
    Shortridge D; Duncan LR; Pfaller MA; Flamm RK
    Int J Antimicrob Agents; 2019 May; 53(5):637-643. PubMed ID: 30716448
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Antimicrobial activity of ceftolozane/tazobactam against Enterobacteriaceae and Pseudomonas aeruginosa in the Czech Republic in 2016].
    Žemličková H; Jakubů V; Fridrichová M
    Klin Mikrobiol Infekc Lek; 2017 Dec; 23(4):132-135. PubMed ID: 29378381
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 89.